Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment
- 26 April 2007
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (17) , 1705-1707
- https://doi.org/10.1056/nejmp078038
Abstract
In this issue of the Journal, Friis-Møller and colleagues (pages 1723–1735) report on results from a prospective observational study involving more than 23,000 patients infected with HIV. The study, called the Data Collection on Adverse Effects of Anti-HIV Drugs (DAD) trial, identified a possible increased risk of myocardial infarction associated with exposure to protease inhibitors but not to nonnucleoside reverse-transcriptase inhibitors. Because randomized studies are rarely well powered for evaluating adverse effects of treatment, well-designed observational studies are important.1 However, such studies raise complex questions concerning both the potential confounding of risk associations and the mechanisms by which treatment might . . .Keywords
This publication has 4 references indexed in Scilit:
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Commentary: We still need observational studies of drugs—they just need to be betterInternational Journal of Epidemiology, 2006
- Evaluating surrogate endpointsControlled Clinical Trials, 2002
- Channeling bias in the interpretation of drug effectsStatistics in Medicine, 1991